tlooto

A recurrent variant in two patients with EMP2-nEDD.

Yunran Peng, N. Cesarato, Tsenka Tomova-Simitchieva, Sisi Zhao, Huijun Wang, Regina C. Betz, Ulrike Blume‐Peytavi, Zhimiao Lin

2026.2.8British Journal of Dermatology

Paper details

Journal
British Journal of Dermatology
Published
2026.2.8
Citations
0
Fields
Medicine

tlooto Summary

Functional studies revealed that the recurrent de novo heterozygous variant in EMP2 exhibited significantly reduced localization at the plasma membrane, disrupting lipid raft integrity and triggering ligand-independent EGFR activation and internalization.

Abstract

We identify a recurrent de novo heterozygous variant (c.11T>C, p.Leu4Pro) in EMP2 as a cause of EMP2-nEDD in two sporadic patients. Functional studies revealed that the variant exhibited significantly reduced localization at the plasma membrane, disrupting lipid raft integrity and triggering ligand-independent EGFR activation and internalization. Consequently, treatment with the EGFR inhibitor erlotinib led to significant clinical improvement in one patient after one month.

Citation format

PENG, Yunran, et al. A recurrent variant in two patients with emp2-nedd. British Journal of Dermatology, 2026, 194(5): 974–976.